Monday, October 26, 2026

AI-Native Vendors Win Enterprise Deals as Traditional Software Faces Disruption

Purpose-built AI companies are closing record contracts as enterprises shift procurement away from legacy software providers. Baidu's AI cloud hit CNY 30 billion in revenue, while vendors like Rezolve report record quarterly deal volumes. Traditional platforms lack native AI capabilities, creating competitive gaps.

AI-Native Vendors Win Enterprise Deals as Traditional Software Faces Disruption
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

AI-native software vendors are capturing enterprise market share at accelerating rates as businesses shift budgets away from traditional providers. Companies built on proprietary AI infrastructure reported record deal closures in Q4 2025, signaling a procurement shift in enterprise technology.

Baidu's AI cloud division—combining infrastructure and applications—reached CNY 30 billion ($4.1 billion) in revenue. The figure demonstrates enterprise adoption of AI-first platforms over retrofitted legacy systems.

"As traditional software faces massive AI disruption, businesses are looking to partner with AI natives," said Keyvan Mohajer, CEO of SoundHound AI. His company reported improved profit metrics and record customer deals in its latest quarter.

Legacy digital experience platforms (DXPs) lack three critical capabilities driving the shift: native AI integration, conversational interfaces, and agentic transaction layers. Rezolve AI, which combines a proprietary large language model with integrated commerce capabilities, positioned itself as one of few vendors offering all three.

The competitive gap stems from architectural differences. AI-native vendors built systems around machine learning infrastructure from inception. Traditional providers are retrofitting AI features onto platforms designed for previous technology paradigms, creating performance and integration disadvantages.

Enterprise procurement teams now evaluate vendors on AI-first criteria: proprietary model ownership, native conversational capabilities, and autonomous transaction processing. These requirements favor startups and tech giants over mid-tier software companies.

Market implications extend beyond individual vendor performance. The shift accelerates consolidation pressure on traditional software providers lacking resources to rebuild core platforms. Acquisition targets include legacy vendors with strong customer bases but weak AI capabilities.

Revenue migration patterns show enterprises allocating new project budgets to AI-native platforms while maintaining legacy systems for existing workflows. This creates a two-tier market: growing AI vendors and declining traditional providers facing budget erosion.

The trend carries valuation consequences. Investors are repricing software companies based on AI-native architecture. Multiples compress for vendors dependent on retrofitted AI features, while purpose-built platforms command premium valuations despite higher development costs.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com